Skip to main content

Search This Blog

Prostate Cancer

Posts

Showing posts from December, 2025

What to know about metastatic prostate cancer

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 04, 2025

Invalid Access Key! Invalid Access Key!

Exploring treatment options in cancer: tumor treatment strategies | Signal Transduction and Targeted Therapy

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 04, 2025

Invalid Access Key! Invalid Access Key!

Dilbert' Comic Strip Creator Scott Adams, 67, Is Battling Metastatic Prostate Cancer Like Former President Joe Biden

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 04, 2025

Invalid Access Key! Invalid Access Key!

What Is Stage 3 Cancer?

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 04, 2025

Invalid Access Key! Invalid Access Key!

Treatment outcomes of dogs with transitional cell carcinoma

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 04, 2025

Invalid Access Key! Invalid Access Key!

Exploring treatment options in cancer: tumor treatment strategies | Signal Transduction and Targeted Therapy

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 02, 2025

Invalid Access Key! Invalid Access Key!

What to know about metastatic prostate cancer

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 02, 2025

Invalid Access Key! Invalid Access Key!

What Is Stage 3 Cancer?

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 02, 2025

Invalid Access Key! Invalid Access Key!

Dilbert' Comic Strip Creator Scott Adams, 67, Is Battling Metastatic Prostate Cancer Like Former President Joe Biden

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 02, 2025

Invalid Access Key! Invalid Access Key!

Treatment outcomes of dogs with transitional cell carcinoma

Get link
Facebook
X
Pinterest
Email
Other Apps

- December 02, 2025

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by billnoll

Popular Posts

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

- November 05, 2019

Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with BRCA1/2 or ATM alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...

10 things to know about neuroendocrine tumors

- January 11, 2025

most common symptoms of lung cancer :: Article Creator Two Unusual Lung Cancer Symptoms You May Have In Your Hands Two subtle hand signals could be early indicators of the UK's deadliest cancer, medical experts have warned. These symptoms may point to lung cancer, recognised as the leading cause of cancer death in the nation. Cancer Research UK figures highlight that it results in approximately 34,800 deaths annually, constituting 21% of all cancer deaths. The high death rate from lung cancer largely stems from its typically late diagnosis; often there are no symptoms during the early stages, and as a result, the cancer frequently goes undetected until it is advanced. The NHS cautions: "Lung cancer does not usually cause noticeable symptoms until it's spread through the lungs or into other parts of the body. This means the outlook for the condition is not as good as many other types of cancer." Therefore, early detection and ...

Cost-free prostate cancer screenings save lives (and we should know) | READER COMMENTARY - Baltimore Sun

- February 28, 2020

To screen or not to screen for prostate cancer is a question that men aged 55 to 69 should decide themselves in consult with their doctors, according to finalized guidance from an influential panel of health care experts. (Frame grab from Associated Press video)

‘How I knew I had pancreatic cancer’: Survivors share their symptoms

- June 03, 2025

mastectomy diagnosis :: Article Creator Jessie J Reveals Early Breast Cancer Diagnosis Before "No Secrets" Release Jessie J speaks to fans, sharing news about early breast cancer diagnosis before the release of her song "No Secrets". British singer-songwriter Jessie J has opened up about her battle with early breast cancer, revealing that she was diagnosed prior to the release of her track "No Secrets" in April. The singer, whose real name is Jessica Ellen Cornish, shared the news with her followers on Instagram on Tuesday. "I was diagnosed with early breast cancer before 'No Secrets' came out," Jessie J explained in her post, emphasising the importance of the word "early." Despite the diagnosis, Jessie expressed gratitude for the early detection, acknowledging the difficulties of cancer while focusing on the positive aspects of her situation. The singer has been undergoing a ...

Progression in Certain Advanced Prostate Cancers Delayed with Lynparza Treatment in Phase 3 Trial - Prostate Cancer News Today

- August 13, 2019

Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi (enzalutamide) or Zytiga (abiraterone) in a Phase 3 trial. The multicenter, open-label PROfound study ( NCT02987543 ) compared the efficacy and safety of Lynparza to that of Xtandi (by Astellas and Pfizer Oncology ) and Zytiga (by Janssen ) in mCRPC patients whose disease had progressed while on these newer hormone treatments. Eligible patients also had a mutation in one of 15 genes involved in the homologous recombination (HR) pathway of DNA repair. Specifically, these benefits were seen in patients with mutations in BRCA1 , BRCA2 , or ATM , the most common among HR gene mutations; the first two are also strongly linked with familial breast and ovarian cancers. Overall, HR mutations occur in approximatel...

GREB1 gene potential drug target for prostate cancer treatment - Drug Target Review

- January 16, 2019

Researchers in the US have discovered how a gene involved in regulating hormone receptors, GREB1, may contribute to drug resistance in some prostate cancer patients. The scientists’ findings suggest that disrupting specific activity of the GREB1 gene could be explored for developing more effective therapies in future. Androgens, a type of male hormone, encourage the growth of prostate cancer cells. Hormone therapies (or ‘antiandrogens’) have been developed to counter this activity. These treatments, which target a protein molecule activated by the hormone – the androgen receptor (AR) – are effective against advanced prostate cancer but are hindered by a type of drug resistance called castration-resistant prostate cancer (CRPC). The most common cause of this resistance is an increase in both the amount and activity of AR. Previous work in this area has shown that increases or mutations in AR are present in over 50 percent of CRPC patients, and that increases in AR are associated w...

CAR T cell therapy put me into complete remission after a non ...

- April 20, 2023

breast treatment :: Article Creator Black Women Should Be Screened For Breast Cancer Earlier: Study Black women have a higher breast cancer mortality rate.Shutterstock Experts believe implicit bias in the medical industry prevents black women from receiving adequate care compared to their white counterparts. "There are systemic issues, access to care issues that really go beyond biology," Dr. Arif Kamal, the chief patient officer for the American Cancer Society, told CNN. "The reality is cancer affects everybody and it does not discriminate. Where the discrimination sometimes occurs is after the diagnosis, and that's really what we need to focus on." Dr. Rachel Freedman, a breast oncologist at the Dana-Farber Cancer Institute who was not involved in the study, told the outlet that while current guidelines do account for cancer risk, "race and ethnicity have not been traditional factors that go into these decision...

“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise

- April 13, 2025

al roker prostate cancer diagnosis :: Article Creator

Sentinel lymph node biopsy: What cancer patients should know

cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...

Genomic analysis identifies potential prostate cancer targets - Drug Target Review

In a recent study more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies. The study outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumours. Using comprehensive genomic profiling (CGP) to analyse thousands of tumour samples from men with advanced prostate cancers, the researchers identified that 57 percent of the samples evaluated had genomic characteristics that suggested the tumours were candidates for targeted therapies. The purpose of this study, co-led by Foundation Medicine and Huntsman Cancer Institute (HCI) at the University of Utah (U of U) , was to analyse prostate tumours using CGP to identify genomic changes to inform potential targeted treatment strategies. CGP analyses tumour samples to identify genomic changes so that, where possible, a patient can be matched to available targeted treatments. “This study demonstrates that routine clinical use of compr...

Archive

December 202510
November 202572
October 202569
September 202598
August 202598
July 202585
June 202596
May 2025107
April 2025106
March 202599

Show more Show less

Labels

"cancer prostata" - Google News
"metastatic prostate cancer" - Google News
"prostate cancer causes" - Google News
"prostate cancer survival rate" - Google News
"prostate cancer treatment options" - Google News
"prostate cancer treatment" - Google News
"prostate cancer" - Google News
"prostatectomy" - Google News
"symptoms of prostate cancer in men" - Google News
cancer+prostata - Google News

Google News
IFTTT
metastatic prostate cancer
metastatic+prostate+cancer - Google News
prostate cancer
prostate cancer causes
prostate cancer survival rate
prostate cancer treatment
prostate cancer treatment options
prostate+cancer - Google News
prostate+cancer+causes - Google News
prostate+cancer+survival+rate - Google News
prostate+cancer+treatment - Google News
prostate+cancer+treatment+options - Google News
prostatectomy
prostatectomy - Google News
symptoms of prostate cancer in men
symptoms+of+prostate+cancer+in+men - Google News

Show more Show less